Browsing Tag

Partnering

580 posts

Pharma COVID Roundup: News from Moderna and J&J
By

By
The latest on COVID-19 vaccines/drugs and manufacturing from Moderna and J&J. Manufacturing and supply of COVID-19 vaccines and drugs Recipharm Site Approved for Mfg of Moderna’s COVID-19 Vaccine Recipharm, a…

Global Pharma Briefs: News from J&J, Viatris, Teva, and GSK
By

By
A roundup of news from Germany (CureVac, Merck KGaA), Israel (Teva, Bioeq), the UK (GSK), and the US (J&J, Viatris, Sanofi, Teva, MacroGenics, and Senti Biosciences). Germany Merck KGaA, BioMed…

GSK, Alector in $2.2-Bn Pact for mAbs for Neurological Diseases
By

By
GlaxoSmithKline (GSK) and Alector, a South San Francisco, California-based clinical-stage bio/pharmaceutical company, have entered into a pact to co-develop monoclonal antibodies (mAbs) for a range of neurodegenerative diseases, in a…

Sanofi Launches Dedicated mRNA Center of Excellence
By

By
Sanofi has launched a dedicated mRNA Center of Excellence with a planned annual commitment of approximately EUR 400 million ($475 million) to develop and deliver mRNA vaccines. The center will…

Global Pharma Briefs: News from J&J, Novartis, Sanofi, and BMS
By

By
A roundup of news from Belgium (Legend Biotech, J&J), Canada (AbCellera), China (Frontera Therapeutics), Ireland (Horizon Therapeutics), Switzerland (Novartis), the UK (Exscientia), and the US (Sanofi, BMS, others). Belgium Legend…

Gilead, Shoreline Biosciences in $2.3-Bn Pact for Allogeneic Cell Therapies
By

By
Kite, part of Gilead Sciences, and Shoreline Biosciences, a San Diego, California-based company developing allogeneic cellular immunotherapies for cancer and other diseases, have entered into a strategic partnership, worth up…

BMS, Eisai Enter $3.1-Bn Pact for Oncology ADC
By

By
Bristol-Myers Squibb (BMS) and Eisai have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of Eisai’s MORAb-202, an antibody drug conjugate (ADC), in a $3.1-billion…

US Gov’t Purchases Additional 200 M Doses of Moderna’s COVID-19 Vaccine
By

By
The US government has purchased an additional 200 million doses of Moderna’s COVID-19 vaccine, and the European Medicines Agency (EMA) has approved a new manufacturing site for the vaccine. Moderna…

GSK, iTeos Therapeutics in $2-Bn Pact for Immuno-Oncology Drug
By

By
GlaxoSmithKline (GSK) and iTeos Therapeutics, a Cambridge, Massachusetts-based bio/pharmaceutical company, have agreed to co-develop and co-commercialize iTeos’ immuno-oncology drug candidate, EOS-448, in a deal worth up to $2.075 billion ($625…

Merck & Co. in $1.2-Bn Supply Pact with US Gov’t for Oral COVID-19 Drug
By

By
Merck & Co. has entered into a procurement agreement, worth up to $1.2 billion, with the US government for molnupiravir, its investigational oral antiviral agent for treating mild-to-moderate COVID-19. Molnupiravir…